Simply Solventless Concentrates Valuation

Is HASH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HASH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HASH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HASH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HASH?

Key metric: As HASH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HASH. This is calculated by dividing HASH's market cap by their current earnings.
What is HASH's PE Ratio?
PE Ratio	41.2x
Earnings	CA$1.24m
Market Cap	CA$51.28m

HASH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.7x
Enterprise Value/EBITDA	21.2x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does HASH's PE Ratio compare to its peers?

The above table shows the PE ratio for HASH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23.8x
MDP Medexus Pharmaceuticals	18.8x	49.9%	CA$60.4m
WOLF Grey Wolf Animal Health	31.6x	n/a	CA$29.2m
GRIN Grown Rogue International	38.8x	n/a	CA$208.9m
YOUR YourWay Cannabis Brands	6x	n/a	CA$23.2m
HASH Simply Solventless Concentrates	41.2x	n/a	CA$51.3m

Price-To-Earnings vs Peers: HASH is expensive based on its Price-To-Earnings Ratio (41.2x) compared to the peer average (29.7x).

Price to Earnings Ratio vs Industry

How does HASH's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?

13 Companies	Price / Earnings	Estimated Growth	Market Cap

13 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: HASH is expensive based on its Price-To-Earnings Ratio (41.2x) compared to the North American Pharmaceuticals industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is HASH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HASH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	41.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HASH's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medexus Pharmaceuticals

CA$60.4m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.45

15.6%

61.2%

Fennec Pharmaceuticals

US$145.9m

Operates as a biopharmaceutical company in the United States.

FRX

US$7.35

30.1%

-38.9%

Verano Holdings

CA$722.2m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.02

-14.8%

-65.2%